Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-29 @ 2:28 AM
Study NCT ID:
NCT01477060
Status:
TERMINATED
Last Update Posted:
2014-02-20
First Post:
2011-11-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
Sponsor:
Fondazione Michelangelo
Organization:
Study Overview
Official Title:
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy
Status:
TERMINATED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was stopped due to insufficient accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Target Population: female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy.
The study rationale is based on the potentiality of reversing endocrine-resistance by Lapatinib
* Activity on compensatory-adaptive mechanisms of hyperactivity of signals generated by HER2 family
* Modulation of energy balance and signals associated to survival through AMPK activation (via Calmodulin) Metformin
* Indirect mechanism, through reduced insulin receptors and IGFR stimulation, with reduces proliferative effects downstream
* Direct mechanism, through AMPK activation (via LKB1), with reduced protein synthesis (mTOR inhibition) and increased availability of intracellular energy Lapatinib and Metformin
* AMPK "Double"activation, through different potentially additional mechanisms.
* Inhibition of proliferative mechanisms for interference on various intracellular target
* IR (A e/o B); IGFR
* EGFR; HER2
Primary objectives :
1\. To assess the rate of patients free from disease progression at 3 months from randomization
Secondary objectives :
1. To assess the overall response rate
2. To assess the duration of response
3. To assess 3-years overall survival rate
4. To assess tolerability of each proposed treatment Female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy will randomized to receive: hormonal therapy + lapatinib or hormonal therapy + metformin or hormonal therapy + metformin + lapatinib with a ratio 1:1:1.
For each arm of the study the following sample size is required:
* First step: 23 patients, for a total of 69 patients in all 3 arms
* Second step: further 33 patients, for a total of 168 patients in all 3 arms.
The study rationale is based on the potentiality of reversing endocrine-resistance by Lapatinib
* Activity on compensatory-adaptive mechanisms of hyperactivity of signals generated by HER2 family
* Modulation of energy balance and signals associated to survival through AMPK activation (via Calmodulin) Metformin
* Indirect mechanism, through reduced insulin receptors and IGFR stimulation, with reduces proliferative effects downstream
* Direct mechanism, through AMPK activation (via LKB1), with reduced protein synthesis (mTOR inhibition) and increased availability of intracellular energy Lapatinib and Metformin
* AMPK "Double"activation, through different potentially additional mechanisms.
* Inhibition of proliferative mechanisms for interference on various intracellular target
* IR (A e/o B); IGFR
* EGFR; HER2
Primary objectives :
1\. To assess the rate of patients free from disease progression at 3 months from randomization
Secondary objectives :
1. To assess the overall response rate
2. To assess the duration of response
3. To assess 3-years overall survival rate
4. To assess tolerability of each proposed treatment Female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy will randomized to receive: hormonal therapy + lapatinib or hormonal therapy + metformin or hormonal therapy + metformin + lapatinib with a ratio 1:1:1.
For each arm of the study the following sample size is required:
* First step: 23 patients, for a total of 69 patients in all 3 arms
* Second step: further 33 patients, for a total of 168 patients in all 3 arms.
Detailed Description:
Treatment Plan Patient will continue to be treated with the same hormone therapy at the same dose, route and schedule
Patients will be randomized to receive:
A: Lapatinib, 1250 mg/die, os B: Metformin, 1500 mg/die, os C: Lapatinib + Metformin, 1250 mg+1500 mg/die, os Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances occur, intolerable toxicities occur, or the patient withdraws consent
Statistical consideration Randomization will be stratified according to the site of metastases: visceral versus non-visceral lesions. The primary objective of this study is to evaluate the rate of patients free of disease progression at 3 months from randomization. The final analysis of this objective will be conducted when a total of 168 patients are enrolled across the three arms. This is the number of patients needed for a test with an experiment-wise alpha = 0.05 and power = 80% to show a statistically significant increment of 10% to the rate of patients without disease progression at 3 months, assuming a rate of 5% for treatments without lapatinib and/or metformin (P0=5% and P1=15%). After having accrued a total of 23 evaluable patients in each arm, the trial design can proceed to step 2 randomizing additional patients to each arm only if two or more patients are free of disease progression at 3 months. Otherwise, the study arm with less than expected responses will be discontinued. In the second stage 33 additional patients will be enrolled in each study arm to reach a total of 56 total patients per arm. If less than 6 patients per arm will be free of disease progression then the increment of corresponding treatment will be considered not significant.
Procedures:
The study will consist of a screening period, a treatment period and follow up for survival Screening Phase
Within 4 weeks prior randomization:
A signed written, informed consent will be obtained prior to any study specific assessments are initiated. The following will be performed prior to randomization
* Radiographic complete assessment of disease status (chest Xray; liver ultrasound, bone scan and CT or MR of target lesions and involved sites)
* Hematology and biochemistry
* Pregnancy test for women of child-bearing potential
* Cardiac assessment with ECG, echocardiography or multi-gated scintigraphic scan (MUGA)
* Medical history, physical examination, vital signs, signs and symptoms of breast cancer lesions, weight, height, ECOG performance status
Treatment Phase:
MONTHLY up to 3 months since randomization
* Physical examination, including clinical disease assessment, ECOG performance status, vital signs
* Hematology and biochemistry
* Safety evaluation (i.e. routine collection of adverse events)
* Patient's compliance
* Concomitant therapy
EVERY 3 MONTHS after the first 3 months of treatment until disease progression is documented, intolerable toxicities occur, or the patient withdraws consent:
* Physical examination, including clinical disease assessment, ECOG performance status, vital signs
* Radiographic disease assessment (using the same methods at screening)
* Hematology and biochemistry
* Safety evaluation (i.e. routine collection of adverse events)
* Concomitant therapy
* Patient's compliance
EVERY 6 MONTHS until disease progression is documented, intolerable toxicities occur, or the patient withdraws consent:
* Complete radiographic assessment
* Assessment of the LVEF using the same method at screening
Afterwards:
EVERY 6 MONTHS after disease progression or trial discontinuation due to intolerable toxicities or other reasons. Patients may receive other therapy following study discontinuation. Patients will continue to be followed for survival for a minimum of 3 years.
Patients will be randomized to receive:
A: Lapatinib, 1250 mg/die, os B: Metformin, 1500 mg/die, os C: Lapatinib + Metformin, 1250 mg+1500 mg/die, os Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances occur, intolerable toxicities occur, or the patient withdraws consent
Statistical consideration Randomization will be stratified according to the site of metastases: visceral versus non-visceral lesions. The primary objective of this study is to evaluate the rate of patients free of disease progression at 3 months from randomization. The final analysis of this objective will be conducted when a total of 168 patients are enrolled across the three arms. This is the number of patients needed for a test with an experiment-wise alpha = 0.05 and power = 80% to show a statistically significant increment of 10% to the rate of patients without disease progression at 3 months, assuming a rate of 5% for treatments without lapatinib and/or metformin (P0=5% and P1=15%). After having accrued a total of 23 evaluable patients in each arm, the trial design can proceed to step 2 randomizing additional patients to each arm only if two or more patients are free of disease progression at 3 months. Otherwise, the study arm with less than expected responses will be discontinued. In the second stage 33 additional patients will be enrolled in each study arm to reach a total of 56 total patients per arm. If less than 6 patients per arm will be free of disease progression then the increment of corresponding treatment will be considered not significant.
Procedures:
The study will consist of a screening period, a treatment period and follow up for survival Screening Phase
Within 4 weeks prior randomization:
A signed written, informed consent will be obtained prior to any study specific assessments are initiated. The following will be performed prior to randomization
* Radiographic complete assessment of disease status (chest Xray; liver ultrasound, bone scan and CT or MR of target lesions and involved sites)
* Hematology and biochemistry
* Pregnancy test for women of child-bearing potential
* Cardiac assessment with ECG, echocardiography or multi-gated scintigraphic scan (MUGA)
* Medical history, physical examination, vital signs, signs and symptoms of breast cancer lesions, weight, height, ECOG performance status
Treatment Phase:
MONTHLY up to 3 months since randomization
* Physical examination, including clinical disease assessment, ECOG performance status, vital signs
* Hematology and biochemistry
* Safety evaluation (i.e. routine collection of adverse events)
* Patient's compliance
* Concomitant therapy
EVERY 3 MONTHS after the first 3 months of treatment until disease progression is documented, intolerable toxicities occur, or the patient withdraws consent:
* Physical examination, including clinical disease assessment, ECOG performance status, vital signs
* Radiographic disease assessment (using the same methods at screening)
* Hematology and biochemistry
* Safety evaluation (i.e. routine collection of adverse events)
* Concomitant therapy
* Patient's compliance
EVERY 6 MONTHS until disease progression is documented, intolerable toxicities occur, or the patient withdraws consent:
* Complete radiographic assessment
* Assessment of the LVEF using the same method at screening
Afterwards:
EVERY 6 MONTHS after disease progression or trial discontinuation due to intolerable toxicities or other reasons. Patients may receive other therapy following study discontinuation. Patients will continue to be followed for survival for a minimum of 3 years.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2011-000155-16 | EUDRACT_NUMBER | None | View |